Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0705-0002 · 1 trial · 2 indications
Measured as number of events.
Measured as number of events.
Measured as hour micromolar (h\*μM).
Measured as percentage (%) of dose.
| Arm | Type | Description |
|---|---|---|
| NNC0705-0002 | EXPERIMENTAL | Participants will receive NNC0705-0002 administered orally as a single ascending dose (SAD), multiple ascending dose (MAD), or under fed/fasted conditions. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC0705-0002 administered orally as a SAD, MAD, or under fed/fasted conditions. |
| Name | Type | Description |
|---|---|---|
| NNC0705-0002 | DRUG | Participants will receive oral capsule of NNC0705-0002. |
| Placebo | DRUG | Participants will receive oral capsule of placebo matched to NNC0705-0002. |
Inclusion Criteria: * Men or women of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 18.5 to 29.9 kilogram per square metre (kg/m\^2) (both inclusive) at screening. * Body weight: greater than or equal to (...
NNC0705-0002 is an investigational small molecule medicine being developed by Novo Nordisk A/S for cardiovascular and cardiometabolic conditions. It is in Phase 1 clinical development and has not been approved for any use. The specific disease indication has not been disclosed.
NNC0705-0002 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is running the compound's clinical program, including a Phase 1 study in healthy volunteers conducted in the Netherlands.
NNC0705-0002 is in Phase 1 clinical development. It is an investigational drug and is not approved for any indication. One Phase 1 trial is currently recruiting, and no trials for this compound have been completed.
NNC0705-0002 is being studied in NCT07797855, titled "A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People." The Phase 1 trial is recruiting 112 healthy adult volunteers in the Netherlands and is randomized, double-blind, and placebo-controlled.
NNC0705-0002 is being tested in a Phase 1 trial enrolling healthy volunteers, with the study listed under healthy volunteers and cardiometabolic diseases. The trial is designed to assess safety in healthy people, and the specific target indication for the drug has not been disclosed.
The Phase 1 trial NCT07797855 is a randomized, double-blind, placebo-controlled study enrolling 112 healthy volunteers aged 18 and older in the Netherlands. It is currently recruiting, and participants are not selected based on a biomarker.